Artelo Biosciences Inc Cash Flow Conversion Efficiency
Artelo Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has a cash flow conversion efficiency ratio of -1.007x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.03 Million) by net assets ($5.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Artelo Biosciences Inc (2014–2025)
Cash flow conversion efficiency of Artelo Biosciences Inc from 2014 to 2025. This chart illustrates how Artelo Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ARTL stock price for real-time trading data and today's change.
Artelo Biosciences Inc Cash Flow Conversion Ratio Explained
Artelo Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Artelo Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artelo Biosciences Inc ranked by their cash flow conversion efficiency. Also see ARTL company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InCoax Networks AB
ST:INCOAX
|
-0.129x |
|
XTL Biopharmaceuticals Ltd
F:H2K2
|
N/A |
|
Ortin Global Limited
NSE:ORTINGLOBE
|
-0.627x |
|
CT UK High Income Ord
LSE:CHI
|
0.007x |
|
Dart Mining NL
AU:DTM
|
-0.035x |
|
RM Plc
LSE:RM
|
-0.081x |
|
Amati AIM VCT plc
LSE:AMAT
|
-0.004x |
|
Tombador Iron Ltd
AU:TI1
|
-0.062x |
Annual Cash Flow Conversion Efficiency for Artelo Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Artelo Biosciences Inc from 2014 to 2025. Review ARTL free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.27 Million | $-8.52 Million | 6.698x | +329.18% |
| 2024-12-31 | $2.86 Million | $-8.35 Million | -2.923x | -318.51% |
| 2023-12-31 | $11.75 Million | $-8.21 Million | -0.698x | -69.21% |
| 2022-12-31 | $19.40 Million | $-8.01 Million | -0.413x | +19.07% |
| 2021-12-31 | $12.04 Million | $-6.14 Million | -0.510x | +54.54% |
| 2020-12-31 | $3.88 Million | $-4.35 Million | -1.122x | -119.37% |
| 2019-12-31 | $5.46 Million | $-2.79 Million | -0.511x | -104.29% |
| 2018-12-31 | $-134.97K | $-1.61 Million | 11.928x | +3097.41% |
| 2017-12-31 | $544.84K | $-216.82K | -0.398x | -129.70% |
| 2016-12-31 | $-13.80K | $-18.49K | 1.340x | +251.72% |
| 2015-12-31 | $15.29K | $-13.50K | -0.883x | -70.39% |
| 2014-12-31 | $29.46K | $-15.27K | -0.518x | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more